Gain a holistic worldview of adverse events
Identifying real-world safety risks requires connecting with the real world – placing your drug life cycle data in the context of the people and products outside of your organization. With the proliferation of new technologies, varying ontologies, and evolving regulations, adverse events (AE) data continues to grow in volume and complexity. Integrating disparate data into your drug safety workflows to run accurate signal detection and prioritize case management now demands not only reliable access to siloed data sources, but confidence in the data itself.
Advance capabilities for identifying adverse events
Enigma Pharmacovigilance powers enterprise technologies to acquire, link, de-duplicate, and explore disparate AE data. Leveraging existing infrastructure, Enigma unifies your siloed internal data with the world’s AE data to create a broad, standardized repository of linked AE information and insight. Safeguard patient health by relying on connected AE data to improve your regulatory reporting and signal tracking capabilities.
Global data perspective
Enigma brings 600 million expertly curated AE data points from around the globe to inform critical drug development and patient safety decision-making processes.
Single source of truth
A centralized source of linked, de-duplicated AE data facilitates more accurate analysis, accelerates post-market requirements, and enables advanced strategies for identification and signal detection.
Learn why leading pharmaceutical companies rely on Enigma to ensure patient safety
Our Pharmacovigilance process
Enigma Pharmacovigilance powers enterprise technologies to acquire, link, de-duplicate, and explore disparate AE data. Leveraging existing infrastructure, Enigma unifies your siloed internal data with the world’s AE data to create a broad repository of linked information and insight.
Timely and reliable data delivery
Enrich your knowledge of AEs on a global scale with structured data from FDA Adverse Event Reporting System (FAERS) and WHO-UMC Vigibase. Our solution aggregates current and historical datasets and delivers new information programmatically to ensure analysis is grounded in the latest data.
Connect public and internal data
Streamline data cleansing and standardization to enable linking across cases and systems. With flexible ontologies to map public AE data to your internal data, our platform consolidates records into a single view that empowers investigators to analyze previously siloed information.
Enriched data for signal intelligence
Improve detection of relationships between drugs and reported side effects. Enigma’s proprietary algorithms remove duplicate case reports and augment cases with in-depth drug property insights to facilitate faster, more accurate analysis of signals.
Visualizing drug life cycles and adverse events
Visit “A Prescription for Healthcare Data,” a world of interactive data visualizations that connect the fragmented pharmaceutical landscape from patent to patient.